We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+32.04%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.4B
AUM Growth
+$1.66B
Cap. Flow
+$453M
Cap. Flow %
7.07%
Top 10 Hldgs %
53.23%
Holding
81
New
14
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$98.5M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$88.5M
3
CRGX
CARGO Therapeutics
CRGX
+$87.8M
4
ALKS icon
Alkermes
ALKS
+$78.3M
5
ARGX icon
argenx
ARGX
+$74.6M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$116M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.5M
3
ILMN icon
Illumina
ILMN
+$25.8M
4
AXNX
Axonics, Inc. Common Stock
AXNX
+$24.8M
5
SCPH
scPharmaceuticals
SCPH
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$359M
$530M 8.28%
17,687,772
– –
IMCR icon
2
Immunocore
IMCR
$1.77B
$417M 6.51%
6,096,387
– –
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$398M 6.21%
6,768,514
– –
AXSM icon
4
Axsome Therapeutics
AXSM
$12.4B
$357M 5.58%
4,489,596
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$352M 5.5%
11,253,551
-322,986
-3% -$7.71M
RARE icon
6
Ultragenyx Pharmaceutical
RARE
$2.68B
$329M 5.14%
6,887,086
+1,481,997
+27% +$57.5M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$37.8B
$314M 4.91%
1,640,559
-42,803
-3% -$7.29M
ARGX icon
8
argenx
ARGX
$56.5B
$254M 3.96%
667,195
+160,000
+32% +$74.6M
BRKR icon
9
Bruker
BRKR
$9.2B
$246M 3.84%
3,344,095
-37,608
-1% -$2.41M
CYTK icon
10
Cytokinetics
CYTK
$11B
$211M 3.29%
2,525,080
-49,118
-2% -$1.78M
PTCT icon
11
PTC Therapeutics
PTCT
$6.36B
$205M 3.2%
7,423,970
+188,774
+3% +$4.32M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.9B
$189M 2.95%
815,191
+505,706
+163% +$88.5M
ARVN icon
13
Arvinas
ARVN
$536M
$173M 2.71%
+4,213,483
New +$98.5M
MASI
14
DELISTED
Masimo
MASI
$171M 2.68%
1,462,400
-39,093
-3% -$3.64M
PEN icon
15
Penumbra
PEN
$12.6B
$167M 2.6%
662,664
-10,707
-2% -$2.37M
NTRA icon
16
Natera
NTRA
$37.2B
$162M 2.54%
2,593,323
-58,460
-2% -$2.92M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.81B
$137M 2.15%
3,463,201
– –
PTGX icon
18
Protagonist Therapeutics
PTGX
$8.79B
$122M 1.9%
5,315,514
-100,000
-2% -$1.75M
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
$120M 1.87%
+5,175,832
New +$87.8M
VCEL icon
20
Vericel Corp
VCEL
$2.33B
$114M 1.79%
3,212,794
-79,079
-2% -$2.75M
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$113M 1.76%
5,197,019
+47,537
+0.9% +$942K
ALKS icon
22
Alkermes
ALKS
$8.8B
$108M 1.69%
3,901,523
+3,012,450
+339% +$78.3M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$98.1M 1.53%
6,947,918
-188,497
-3% -$2.21M
TXG icon
24
10x Genomics
TXG
$5.85B
$86.7M 1.35%
1,549,951
+29,995
+2% +$1.31M
AKRO
25
DELISTED
Akero Therapeutics
AKRO
$83.9M 1.31%
+3,592,759
New +$70.9M
1
2 3 4

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2023 Portfolio in Review

As of Q4 2023, RTW Investments held 81 positions worth $6.4B, up 35% from $4.74B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

RTW Investments deployed $453M of net new capital in Q4 2023, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Arvinas: 4,213,483 shares worth $173M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $116M trimmed.

  • RTW Investments's largest Q4 2023 buy was Arvinas: 4,213,483 shares worth $173M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q4 2023, an estimated $88.5M increase.
  • RTW Investments's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $116M.
  • RTW Investments fully exited MoonLake Immunotherapeutics in Q4 2023, selling an estimated $28.5M.
  • RTW Investments's ten largest holdings make up 53% of its $6.4B portfolio in Q4 2023.
  • RTW Investments opened 14 new positions and closed 17 in Q4 2023.
  • RTW Investments's portfolio value rose 35% quarter-over-quarter to $6.4B.

Based on RTW Investments's 13F filing for Q4 2023, filed 14 Feb 2024.